Nonalcoholic Steatohepatitis Clinical Trials
Here are the 6 most popular medical studies for nonalcoholic steatohepatitis
Thiazolidinedione
Rosiglitazone for Non-alcoholic Fatty Liver Disease
The purpose of this study is to evaluate the efficacy of rosiglitazone alone compared with rosiglitazone plus metformin or rosiglitazone plus losartan in the treatment of biopsy proven nonalcoholic steatohepatitis (NASH). This study was designed to answer the question: are there differences in the efficacy (as measured by histopathology and insulin resistance) of three different therapeutic modalities used to treat NASH?
Hormone Therapy
Thyroid Hormone for Nonalcoholic Steatohepatitis
This trial is testing whether low-dose thyroid hormone can help treat NASH by improving fat breakdown in mitochondria. The study will happen in two stages, with an interim analysis to determine if the trial should continue. If successful, this could provide new information and strategies for treating NASH in Veterans.
ELF Test for Non-alcoholic Fatty Liver Disease
This trial is testing whether making the results of an ELF test available to treating hepatologists will result in more appropriate and targeted use of liver biopsy in patients with elevated liver enzymes or fatty liver.
Popular filter options for nonalcoholic steatohepatitis trials
Non-alcoholic Fatty Liver Disease Clinical Trials
View 27 Non-alcoholic Fatty Liver Disease medical studies.
Monoclonal Antibodies
GSK4532990 for Non-alcoholic Fatty Liver Disease
This trial aims to investigate how the drug GSK4532990 is processed in the body and how it affects the liver. The study will also assess the safety and tolerability of the drug. Participants
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
NAFLD Clinical Trials
View 27 NAFLD medical studies.
Monoclonal Antibodies
GSK4532990 for Non-alcoholic Fatty Liver Disease
This trial aims to investigate how the drug GSK4532990 is processed in the body and how it affects the liver. The study will also assess the safety and tolerability of the drug. Participants
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Nonalcoholic Steatohepatitis Clinical Trials With No Placebo
View 32 nonalcoholic steatohepatitis medical studies that do not have a placebo group.
Monoclonal Antibodies
GSK4532990 for Non-alcoholic Fatty Liver Disease
This trial aims to investigate how the drug GSK4532990 is processed in the body and how it affects the liver. The study will also assess the safety and tolerability of the drug. Participants
Behavioural Intervention
Low-Fructose Diet for Fatty Liver Disease in Youth
This trial will compare how two different diets (high vs low in high fructose corn syrup or HFCS) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with non-alcoholic fatty liver disease (NAFLD).
Microbiota Therapy
Fecal Microbiota Transplantation for Non-alcoholic Fatty Liver Disease
Nonalcoholic steatohepatitis (NASH) is common, may progress to cirrhosis and is predicted to become a leading indication for liver transplantation in the near future. Though often associated with obesity and the metabolic syndrome, our current understanding of disease development is limited and there are few therapeutic options. Imbalance of gut bacteria is suspected to play a key role driving the progression of fatty liver disease and there is hope manipulation of these bacteria may be beneficial. This study will determine if fecal microbiota transplantation, using stool from lean donors, is an effective and safe treatment for NASH.
Behavioural Intervention
Weight Loss for Obesity and Metabolic Syndrome
This trial is investigating how fat is stored in organs, and why this impacts some people's health more than others. The findings could lead to better treatments for diabetes and cardiovascular disease.
Procedure
Surgical vs. Lifestyle Interventions for Type 2 Diabetes
This trial is being done to compare the effectiveness of two types of bariatric surgery against an intensive lifestyle intervention in promoting weight loss and improvements in Type 2 diabetes in moderately obese patients.
View More Nonalcoholic Steatohepatitis Trials
See another 13 medical studies focused on nonalcoholic steatohepatitis.
Frequently Asked Questions
Introduction to nonalcoholic steatohepatitis
What are the top hospitals conducting nonalcoholic steatohepatitis research?
In the realm of nonalcoholic steatohepatitis (NASH) clinical trials, several hospitals across the United States are making remarkable strides in research and treatment. Based in Miami Lakes, Panax Clinical Research leads the way with four active NASH trials and a total of eight conducted studies to date. Their first recorded trial focusing on this liver condition took place in 2019, demonstrating their commitment to advancing knowledge and potential cures for NASH. Meanwhile, located in San Antonio, Texas Liver Institute is also actively involved with three ongoing NASH trials and an impressive record of eight past investigations since initiating their earliest trial back in 2015.
Another noteworthy institution contributing to NASH research is Impact Research Institute based in Waco. They have three currently active clinical trials dedicated to combating this complex disease, building upon a foundation of six previous studies that commenced from their inaugural NASH trial held as recently as 2020. Tandem Clinical Research located in Marrero has equally made significant contributions with its ongoing participation in three current nonalcoholic steatohepatitis trials and an impressive tally of thirteen prior investigations since embarking on its initial trial journey back in 2017.
Rounding out our list is Catalina Research Institute LLC situated Montclair which participates actively through two present-day projects aimed at tackling nonalcoholic steatohepatitis while preserving legacy built by facilitating six earlier attempts starting officially during 2018.Finding effective treatments for NASH continues to be a challenge but these top hospitals' dedication ensures progress towards understanding this increasingly prevalent condition affecting countless individuals around the country.
These institutions have taken up the mantle not only as pioneers but also as beacons of hope for those affected by nonalcoholic steatohepatitis - showcasing unwavering commitment toward finding answers and improving outcomes for patients everywhere
Which are the best cities for nonalcoholic steatohepatitis clinical trials?
When it comes to nonalcoholic steatohepatitis clinical trials, several cities emerge as leading hubs for research and advancement. San Antonio, Texas stands out with 30 active trials exploring treatments like TVB-2640, HTD1801, and Saroglitazar Magnesium 2 mg. Miami, Florida follows closely behind with 23 ongoing studies focusing on interventions such as Saroglitazar Magnesium 2 mg, TVB-2640, and BOS-580. Additionally, Miami Lakes in Florida offers 11 active trials examining potential treatments like EFX and HTD1801. Rounding out the list are Dallas in Texas and Tucson in Arizona with their respective contributions of 11 and 10 active trials investigating various therapies including Tirzepatide and Semaglutide (SEMA). These cities serve as epicenters of NASH research where individuals can access cutting-edge clinical trials that hold promise for improved management of this condition.
Which are the top treatments for nonalcoholic steatohepatitis being explored in clinical trials?
Clinical trials are actively exploring potential treatments for nonalcoholic steatohepatitis (NASH), a liver disease with limited treatment options. Among the top contenders is EFX, which is currently being tested in two active trials dedicated to NASH. With its first listing in 2019, EFX shows promise as a potential therapeutic option for this condition. Another avenue of exploration lies in dietary intervention, which has shown encouraging results thus far. One ongoing trial and two all-time NASH trials have focused on evaluating the impact of dietary changes on managing this disease since 2015. These research efforts bring hope for improved treatment strategies and outcomes for individuals living with NASH.
What are the most recent clinical trials for nonalcoholic steatohepatitis?
Exciting advancements are being made in the field of nonalcoholic steatohepatitis (NASH) research, with recent clinical trials offering potential breakthroughs for treatment. These include BI 3006337 dose group 4, a Phase 1 trial that became available on August 2nd, 2023. Additionally, HU6 Planned doses and Pemvidutide have shown promise in Phase 2 trials for NASH. Efinopegdutide has also demonstrated potential benefits as a treatment option for NASH patients. With these innovative studies underway, there is hope on the horizon for those affected by this complex liver disease.
What nonalcoholic steatohepatitis clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of nonalcoholic steatohepatitis (NASH), a liver condition characterized by inflammation and fat accumulation. Altimmune, Inc., completed two trials for their ALT-801 therapy in September 2021 and March 2022, respectively. Additionally, BIO89-100 from 89bio, Inc. underwent a trial that concluded in August 2021. Merck Sharp & Dohme Corp.'s Efinopegdutide 20 mg/mL trial finished in August 2021 as well. These accomplishments highlight ongoing efforts to combat NASH and provide hope for patients seeking effective treatments for this challenging condition.